Patrick Toomey actually said...

"That can be very disruptive for the ability of the end user to hedge risks and, therefore, very problematic."

"If we do have global uniformity, then that obviates the need for extraterritoriality in our regulations in the first place."

"It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet."

"You know, Pennsylvania is a home to a very large number of very, very successful bio companies."